The ruling means that barring a settlement or a reversal on appeal, Sanofi and Regeneron could be forced to stop selling Praluent within 6 weeks.
A federal judge said Monday that Sanofi and Regeneron cannot sell the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor Praluent (alirocumab) during their appeal of her earlier ruling in a patent dispute. Barring a settlement or a reversal, the drug makers could be forced to stop selling the cholesterol-fighting drug within 6 weeks.
US District Judge Sue Robinson issued an order Thursday that Sanofi and Regeneron must pull Praluent from the market for 12 years, following a March 2016 jury finding that the companies violated Amgen’s patents for Repatha (evolocumab). Amgen announced Monday’s ruling, in which Robinson extended the start of her injunction barring Praluent sales from 30 to 45 days.
The high-profile case could mean that Amgen would control the US market for the powerful PCSK9 inhibitors, which dramatically reduce low-density lipoprotein (LDL) cholesterol by targeting a protein in the liver.
The rival drugs were approved in July (Praluent) and August (Repatha) of 2015 after a fierce battle to be the first to the market. Sanofi paid for a priority review voucher to jump ahead of Amgen in the FDA queue. Both drugs had initial wholesale prices above $14,000, which prompted payers and pharmacy benefit managers to implement strict protocols for who could gain access.
“Amgen respects the court’s thoughtful deliberations in a situation where a competitor made the choice to launch at risk during the pendency of a patent lawsuit within months of an expedited trial date,” the company said in its statement.
Sanofi and Regeneron, meanwhile, said in a statement they will take their case to the US Circuit Court of Appeals. Regeneron CEO Len Schleifer told attendees at the JP Morgan Healthcare Conference that he was surprised by Amgen’s push for the injunction, and as well as Amgen’s position that “they have to take these products from patients and disrupt it right now. I just don’t think that’s in the interest of the patients, the judge doesn’t think that was in the interest of the public, and I just think that’s a mistake,” Schleifer said.
Homelessness Compounds Hospital Stay Challenges: Study Reveals Prolonged Discharge Struggles
March 28th 2024In this investigation, outcomes of interest were morbidity rate and length of hospital stay or a traumatic injury among a homeless population, and whether age and/or injury severity had an influence on that relationship—with implications for improving the discharge process for these patients.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Risk for Second Primary Melanoma Increases After Primary Melanoma Diagnosis as Men Age
March 28th 2024A population-based cohort study out of Norway has found that older men have a higher risk of developing second primary invasive melanoma following an initial primary melanoma, suggesting the benefits of increased surveillance in these patients.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Wearable Activity Tracker Data Enhance Patient Assessment in Lung Cancer
March 28th 2024This analysis included 119 patients with advanced lung cancer, who were evaluated on 3 facets of physical activity over 14 days of using the amuelink wearable device from Sony: metabolic equivalent tasks, distance walked, and steps taken.
Read More
CMS released a final rule to help patients obtain Children’s Health Insurance Program (CHIP) coverage and issued a proposed rule to update Medicare payment policies and rates for inpatient rehabilitation facilities; debate over if gift card incentives are acceptable in health care marketing.
Read More